How Unstable Angina Is Diagnosed, Scored, and Treated

Unstable angina is chest pain or pressure caused by reduced blood flow to the heart that strikes unpredictably, often at rest or with minimal exertion, and signals that a heart attack could be imminent. Unlike stable angina, which follows a predictable pattern during exercise and fades with rest, unstable angina represents a sudden worsening: episodes become more frequent, more severe, or appear for the first time without an obvious trigger. The condition sits on a continuum with heart attacks, and where exactly to draw the line has become one of the more contested questions in modern cardiology.

What Happens Inside the Artery

The root cause is almost always a cholesterol-laden plaque inside a coronary artery that cracks, erodes, or ruptures. Once the plaque’s surface breaks open, the body treats it like a wound and starts forming a blood clot. These clots are made up of clumped platelets and large amounts of fibrin, a sticky protein produced when tissue factor inside the plaque activates the clotting cascade.¹ In unstable angina, the clot partially blocks the artery or blocks it briefly before breaking up on its own. The heart muscle downstream gets starved of oxygen long enough to cause pain, but not long enough to die. If the clot grows large enough to completely seal the vessel for a sustained period, the result is a heart attack.

Not every plaque rupture leads to trouble. Many clots form and dissolve without ever growing big enough to significantly obstruct blood flow. Whether a clot becomes dangerous depends on the size of the rupture, how much tissue factor the plaque releases, and how sticky the person’s blood is at that moment. This is part of why unstable angina can be so unpredictable: a plaque that has been quietly growing for decades can cause a crisis overnight, while a larger plaque may sit there indefinitely without incident.

How Doctors Tell It Apart From a Heart Attack

The critical distinction between unstable angina and a heart attack, specifically the type called NSTEMI (a heart attack without a dramatic ECG signature), comes down to whether heart muscle cells actually die. When they do, proteins called troponins leak into the bloodstream. In unstable angina, troponin levels stay normal because the heart muscle was deprived of oxygen but survived. In NSTEMI, troponins rise because some cells were destroyed. Both conditions can feel identical to the patient and may look similar on an electrocardiogram.

The ECG itself provides important clues, though. In the TIMI III Registry, new ST-segment shifts of at least 1 mm appeared in about 14% of patients with unstable angina or non-Q-wave heart attacks, while isolated T-wave inversion showed up in roughly 22%.² Those ST-segment changes carried real prognostic weight: by one year, death or heart attack occurred in 11% of patients with significant ST deviation compared with about 8% of those with no ECG changes. Even subtler shifts of just half a millimeter, and left bundle branch block, turned out to identify higher-risk groups.

Specific ECG patterns matter beyond just the presence or absence of changes. An older but striking study of 32 patients found that when ST depression was accompanied by peaked negative T waves in the precordial leads, 70% of those patients had blockage of the left main coronary artery, the vessel whose obstruction carries the highest mortality risk.³ In-hospital mortality in that group was significantly higher. Patterns like these help emergency physicians move faster toward catheterization in particular patients.

The Shifting Boundary With NSTEMI

One of the most interesting developments in this field over the past decade is that unstable angina diagnoses have dropped sharply, not because fewer people are having coronary events, but because newer blood tests are catching damage that older tests missed. High-sensitivity troponin assays can detect far smaller amounts of heart-muscle injury than the previous generation of tests. Many patients who would have been labeled “unstable angina” a decade ago now test positive for tiny amounts of troponin and get reclassified as having NSTEMI instead.⁴

A study using the Swedish SWEDEHEART registry showed that the proportion of unstable angina among all non-ST-elevation acute coronary syndromes went from about 9% in 2009-2010 to roughly 15% in subsequent years after implementing a more sensitive troponin assay. That sounds paradoxical at first: shouldn’t the proportion go down, not up? It did in many settings, but the Swedish data showed that a relative increase of 13% in unstable angina admissions appeared alongside a larger migration of cases into NSTEMI, largely because more patients were being tested overall.⁵ The 2021 AHA/ACC chest pain guidelines acknowledged this shift, noting that with high-sensitivity troponin, unstable angina becomes less frequent as a diagnosis while type 2 heart attacks (those caused by a mismatch between oxygen supply and demand rather than a ruptured plaque) become more common.⁶

One study examining this reclassification problem found that roughly one in five patients diagnosed with unstable angina could have been reclassified as NSTEMI when high-sensitivity troponin levels and angiographic findings were applied together.⁷ This matters because whether you carry a diagnosis of unstable angina versus NSTEMI affects how aggressively you’re treated and how closely you’re followed. Interestingly, patients with unstable angina who showed evidence of some myocardial injury had a similar risk of death compared with NSTEMI patients who had moderately elevated troponin, though their risk of a recurrent heart attack was lower.⁸ The boundary between the two conditions is genuinely blurry, and the line keeps moving as lab technology improves.

How Risk Is Scored

Not every patient with unstable angina faces the same level of danger, so doctors use structured scoring systems to sort patients into risk categories. The two most widely used are the TIMI score and the GRACE score. Both combine clinical variables like age, heart rate, blood pressure, kidney function, and ECG findings to estimate the likelihood of death or another cardiac event in the short and long term.

The evidence fairly consistently shows that GRACE outperforms TIMI for predicting mortality in patients with non-ST-elevation events. In one head-to-head comparison, the GRACE score achieved strong discrimination for in-hospital mortality while the TIMI score for unstable angina and NSTEMI performed barely better than a coin flip.⁹ For six-month mortality, a similar gap persisted. Another study in East Asian patients confirmed that GRACE was the stronger predictor for both in-hospital and long-term outcomes.¹⁰ A study of Chinese patients with acute heart attacks similarly found GRACE to be more accurate for long-term mortality prediction.¹¹

The tradeoff is complexity. The TIMI score uses fewer variables and can be calculated at the bedside in minutes, which is why it remains popular in busy emergency departments. GRACE requires more inputs, including kidney function and heart-failure status, and typically needs a calculator. For patients with ST-elevation heart attacks, the two scores performed similarly, so the GRACE advantage is specifically pronounced in the unstable angina and NSTEMI population, exactly the group where risk stratification is hardest.

Treatment in the Hospital

Initial treatment focuses on stabilizing the plaque, preventing the clot from growing, and restoring adequate blood flow. Nearly all patients receive antiplatelet therapy (aspirin plus a second agent) and anticoagulation. For the anticoagulant piece, low-molecular-weight heparins like dalteparin have become a practical alternative to traditional intravenous unfractionated heparin. A study of nearly 1,500 patients found similar rates of death, heart attack, or recurrent angina between the two approaches during the first six days, suggesting that the subcutaneous injection form is a reasonable substitute for the IV drip.¹² This is a practical advantage in hospitals without continuous infusion monitoring capacity and for getting patients mobilized sooner.

The bigger treatment question is whether to proceed directly to catheterization and stenting (the invasive strategy) or to stabilize first with medications and reserve catheterization for patients whose symptoms recur or whose stress tests look bad (the conservative strategy). A Cochrane systematic review concluded that early invasive treatment is preferable for unstable angina and NSTEMI.¹³ The landmark FRISC II trial showed that the invasive approach reduced the combined rate of death or heart attack from about 12% to roughly 9% at six months, and symptoms of angina and hospital readmissions were cut in half.¹⁴ The benefit was most pronounced in higher-risk patients, those with ECG changes or elevated biomarkers. Lower-risk patients with normal troponins and no ECG changes saw a smaller advantage, which is one reason the conservative approach hasn’t been entirely abandoned.

Long-Term Outlook

The first weeks after an unstable angina episode are the most dangerous. One long-term follow-up study found that the risk of death or heart attack was highest in the first six to eight weeks after admission, and that ECG findings at admission, particularly ST depression and transient signs of ischemia, were the strongest predictors of trouble.¹⁵ Continuous monitoring during that study picked up silent ischemic episodes in some patients whose standard ECGs looked normal, and 72% of that group went on to have an adverse event.

Beyond those initial weeks, the picture brightens. A study tracking patients for a median of nearly eight years found that mortality ran about 6% in the first year after an unstable angina diagnosis, then dropped to 2-3% annually in subsequent years. Nearly half of patients underwent revascularization in the first year, and the rate of heart attacks was around 11% in year one but fell to 1-3% per year afterward.¹⁶ The message is that the early phase is turbulent, but patients who get through it with appropriate treatment tend to do reasonably well. That early period is exactly why aggressive risk stratification and timely intervention matter so much.

Rehabilitation and Long-Term Prevention

After the acute crisis passes, the goal shifts to preventing the next one. High-intensity statin therapy started within two weeks of an acute coronary event has been associated with roughly a 20% reduction in the risk of a subsequent adverse coronary event over two years, including reductions in cardiovascular death, recurrent unstable angina, and the need for repeat revascularization.¹⁷ These benefits took more than four months to begin accumulating, which underscores why adherence matters even when you feel fine.

Cardiac rehabilitation is another pillar of recovery, though it’s underused. A structured rehab program for one patient with unstable angina who had exhausted other options increased his symptom-free walking distance to 400 meters at discharge, and he was walking at least a kilometer daily during nine months of follow-up.¹⁸ A larger controlled trial of rehab combined with ongoing structured education found that patients in the intervention group had lower rates of recurrent unstable angina and heart attack over 12 months, along with improvements in cholesterol levels, blood pressure, and heart function.¹⁹ Angina symptoms, physical mobility, and treatment satisfaction all improved in the rehab group. The evidence suggests that regular, supervised exercise does not just improve fitness; it changes the trajectory of the disease.

When Chest Pain Strikes Without Blocked Arteries

Not all angina comes from plaque rupture. Prinzmetal’s (variant) angina is caused by sudden spasms of a coronary artery that temporarily choke off blood flow, and it can happen in arteries that are completely free of plaque buildup. It typically strikes at rest, often in the early morning hours, and produces ST-segment elevation on the ECG, mimicking a major heart attack. The mechanism appears to involve a mix of endothelial damage and vasoactive substances that trigger intense contraction of the vessel wall.²⁰ Treatment centers on calcium channel blockers and nitrates rather than the antiplatelet and anticoagulant cocktail used for classic unstable angina.

An even broader category is ischemia with nonobstructive coronary arteries, or INOCA. These patients have genuine ischemia, their heart muscle isn’t getting enough blood during stress or sometimes at rest, but their major coronary arteries look open on angiography. The problem lies in the tiny vessels that the catheter can’t see: coronary microvascular dysfunction, where the small vessels fail to dilate properly under stress.²¹ INOCA patients frequently endure recurrent chest pain without effective treatment and have been shown to face poor clinical outcomes.²² For years, many of these patients were told their angiograms were “clean” and sent home without further workup, which has only recently started to change as the cardiology community recognizes microvascular disease as a genuine and treatable problem.

Gender Differences in Presentation

Women with unstable angina tend to present differently from men in ways that can delay recognition. In one study of sex-based differences, women were older at presentation, more likely to have a history of high blood pressure, and less likely to report the classic pattern of substernal crushing chest pain that medical training emphasizes.²³ They were also less likely to be referred for invasive evaluation. Despite these differences in how they showed up and how they were treated, the duration of unstable symptoms before reaching a hospital was similar in men and women.²⁴ The gap, in other words, wasn’t in how quickly women sought care but in how the system responded once they arrived. This pattern of less aggressive evaluation in women has been documented repeatedly across cardiology and remains an active area of quality-improvement work.

The Psychological Aftermath

Having an acute coronary event, whether it’s unstable angina or a full heart attack, is a traumatic experience in the clinical sense of the word. A meta-analysis estimated that about 12% of acute coronary syndrome survivors develop clinically significant symptoms of post-traumatic stress disorder, and those who do face roughly double the risk of recurrent cardiac events or death compared with patients who don’t develop PTSD.²⁵ That doubling of risk isn’t just a statistical footnote; it creates a feedback loop where psychological distress drives physiological stress responses that make the underlying heart disease worse.

A study of patients admitted for acute coronary syndromes found that about 15% met conservative criteria for PTSD at three months, and the strongest predictors were not the severity of the cardiac event itself but rather the patient’s psychological state during the admission: acute stress symptoms, depression, hostility, and the intensity of chest pain all independently predicted who would go on to develop PTSD.²⁶ This means the seeds of long-term psychological harm are planted early, often while the patient is still in the hospital, and screening during that window could identify people who need support before the problem becomes entrenched.

Emerging Therapeutic Directions

One of the more intriguing recent developments is the investigation of anti-inflammatory drugs as add-on therapy after acute coronary events. Colchicine, an old gout medication, has drawn attention because atherosclerosis is fundamentally an inflammatory disease. A meta-analysis of eight randomized trials involving over 13,000 patients found that colchicine modestly reduced major adverse cardiovascular events compared with placebo or standard treatment.²⁷ The effect was statistically marginal, meaning it just barely cleared the threshold for significance, and the right dose, timing, and patient population are still being worked out. But the concept, attacking the inflammatory process that makes plaques unstable rather than just treating the downstream clotting, represents a genuine shift in how researchers think about preventing the next coronary event. Whether colchicine becomes a standard prescription after unstable angina or remains a niche option will depend on larger, longer trials now underway.